Medications can affect people differently after a brain injury. They can help treat some effects of brain trauma and the resulting emotional and psychological changes following an injury. However, there is insufficient evidence to establish guidelines for optimal pharmocotherapy medications that may be used to support recovery. When the decision is made to use medications to promote TBI recovery or treat the related disabilities, clinicians, staff, or family members, should thoroughly document the goals of pharmacotherapy and monitor for side effects to ensure the efficacy of treatment.
The choice of pharmacologic treatment for cognitive, behavioral, or affective disorders following TBI depends upon an accurate assessment of the underlying disorder responsible for the clinical picture presented. The differential diagnosis should be based on: pre-injury diagnosis, neuropsychological disorders, sensorimotor disorders, medical disorders, adverse effects of medications, reactive mood and anxiety disorders, and sleep disorders.
Recent literature reviews analyzing the economic burden of traumatic brain injury indicate that this type of analysis is relatively new, and has been subject to numerous attempts at quantification through varying methods. However, the potential cost savings both to the individual and/or society, as a whole, through successful TBI rehabilitation programs is substantial. Neurobehavioral programs with a behavior analytic focus are effective at documenting and analyzing the impact of medication interventions as well as implementing behavioral interventions to verify the cost effectiveness of treatments.